<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322464</url>
  </required_header>
  <id_info>
    <org_study_id>GWCP0601</org_study_id>
    <nct_id>NCT01322464</nct_id>
  </id_info>
  <brief_title>Study to Assess Food Effect on Sativex Bioavailability</brief_title>
  <official_title>A Phase I Study to Assess the Effect of Food on the Single-Dose Bioavailability of Sativex, and to Compare the Single and Multiple Dose Pharmacokinetics of Sativex at Three Dose Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GW Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess effect of food on the bioavailability of a single dose of Sativex and to
      measure its' pharmacokinetics after a single and multiple doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomised, ascending dose, 2-way crossover food-effect study
      incorporating a parallel single and multiple dose components in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary PK Endpoints</measure>
    <description>Cmax, AUC(0-inf), T-half and CL/F: under fasting conditions (Group 1, Day 1 and 4 fasted data) and under fed conditions (Group 1 Day 1 and 4 fed data)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary PK measures</measure>
    <description>Cmax, Tmax, AUC(0-t), t-half, CL/F, Varea/F from Day 4 (Groups 2 and 3) and from fasted subjects on days 1 and 4 (Group 1) Cmax, Cmin, Tmax, AUC(0-t), Flux from Day 12 data (all groups)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Sativex</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Food Effect</condition>
  <arm_group>
    <arm_group_label>Group 1 Fasted-Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.
Followed by 4 sprays daily in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Fed-Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.
Followed by 4 sprays daily in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 sprays Sativex daily in fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 sprays sativex daily in fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex</intervention_name>
    <description>4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.</description>
    <arm_group_label>Group 1 Fasted-Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex</intervention_name>
    <description>4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.</description>
    <arm_group_label>Group 1 Fed-Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex</intervention_name>
    <description>2 sprays Sativex daily in fasted state Days 4-13.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sativex</intervention_name>
    <description>8 sprays Sativex daily in fasted state Days 4-13.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males between 18 and 45 years of age (inclusive).

          -  Body mass index to be between 18 to 30 kg/m2 (inclusive) as calculated by
             weight(Kg)/height(m2).

          -  Subjects were to have no clinically significant abnormal findings on physical
             examination, ECG, medical history, or clinical laboratory results during screening.

          -  Subjects were to, in the opinion of the investigator, have no clinically significant
             abnormal findings of renal and hepatic function as determined by serum creatinine,
             total bilirubin, and transaminase levels.

          -  Subjects were to be non-users of tobacco products (minimum of 6 months prior to the
             start of the study).

          -  Subjects were to have a negative screen for HIV I and II, HBsAg, and antibody to
             Hepatitis C virus.

          -  Subjects were to have a negative urine screen for alcohol, drugs of abuse (screening
             only), and cotinine.

          -  Subjects were to use an appropriate barrier method of contraception (condom and
             spermicide) in addition to having their female partner use another form of barrier
             contraception (e.g.female condom or occlusive cap with spermicide) during the study
             and for 3 months following administration of the study drug.

          -  Subjects were able to comply with the protocol and the restrictions and assessments
             therein.

          -  Subjects were to give voluntary written informed consent to participate in the trial.

        Exclusion Criteria:

          -  Subjects were not to have a history or presence of significant cardiovascular,
             pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic,
             dermatologic, neurologic, or psychiatric disease.

          -  Subjects were not to have any history or presence or family history of schizophrenia,
             other psychotic illness, severe personality disorder, depression, or other significant
             psychiatric disorder.

          -  Subjects were not to have a postural drop of 20 mmHg or more in systolic blood
             pressure at screening.

          -  Subjects were not to have participated in a previous clinical trial within 90 days
             prior to study initiation.

          -  Subjects were not to have donated plasma within 90 days prior to study initiation.

          -  Subjects were not to have donated blood within 90 days prior to study initiation.

          -  Subjects were not to have had an abnormal diet or substantial changes in eating habits
             within 30 days prior to study initiation.

          -  Subjects were not to have had treatment with any known enzyme-altering agents
             (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the
             study.

          -  Subjects were to have no history of known hypersensitivity or idiosyncratic reaction
             to the study drug or related compounds.

          -  Subjects were not to use any prescription medication within 14 days prior to or during
             the study.

          -  Subjects were not to use any over-the-counter medication within 7 days prior to or
             during the study.

          -  Subjects were not to have a history of alcohol or drug abuse within 2 years prior to
             the study (subjects with a history of previous use of cannabis were not excluded
             unless they had used cannabis or cannabinoid based medicine within 30 days prior to
             study drug administration or were unwilling to abstain for the duration of the study).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guy's Drug Research Unit, Quintiles Ltd.</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013 Apr;69(4):825-34. doi: 10.1007/s00228-012-1393-4. Epub 2012 Oct 4.</citation>
    <PMID>23052407</PMID>
  </results_reference>
  <results_reference>
    <citation>Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013 May;69(5):1135-47. doi: 10.1007/s00228-012-1441-0. Epub 2012 Nov 22.</citation>
    <PMID>23179176</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sativex</keyword>
  <keyword>bio-availability</keyword>
  <keyword>cannabinoid</keyword>
  <keyword>pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

